Figure 3.

The effect of a reduction in lung pH and renal impairment on the plasma and lung exposure of chloroquine (CQ) relative to in vitro half‐maximal effective concentration (EC₅₀) values for two dosing regimens. (a–c) There was 600 mg b.i.d. administered for 10 days (ClinicalTrials.gov Identifier: NCT04323527); (d–f) 300 mg q.d. for 4 days, followed by 150 mg q.d. (ClinicalTrials.gov Identifier: NCT04333732).Total plasma (red line), lung mass total (blue solid line), lung mass unbound (blue dashed line), epithelial lining fluid (ELF; yellow line) are shown. R_EC₉₀: Ratio of the simulated lung mass unbound concentration to effective concentration 90% (EC₉₀) value (6.9 µM) against severe acute respiratory syndrome‐coronavirus 2 virus in Vero E6 cells. GFR, glomerular filtration rate.